| Literature DB >> 30473785 |
Isabel Morales Barroso1,2,3, Lorena López-Cerero1,2, María Dolores Navarro1,2, Belén Gutiérrez-Gutiérrez1,2, Alvaro Pascual1,2, Jesús Rodríguez-Baño1,2.
Abstract
Background: Escherichia coli sequence type 131 (ST131) is a successful clonal group that has dramatically spread during the last decades and is considered an important driver for the rapid increase of quinolone resistance in E. coli.Entities:
Keywords: Carriage; Escherichia coli; Intestinal colonisation; Outcome; Prevalence colonization; Risk factors; ST131
Mesh:
Substances:
Year: 2018 PMID: 30473785 PMCID: PMC6238289 DOI: 10.1186/s13756-018-0427-9
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Distribution of participants
Characteristics of ST131 E. coli colonized and non-colonized household members of index community patients. Data are expressed as number of exposed patients (percentage) except where specified
| Features of contacts (individual level) | ST 131 colonized household members ( | Non-ST131 colonized household members ( |
| Adjusted OR (multilevel) |
|
|---|---|---|---|---|---|
| Median age in years (IQR) | 55 (47.25–74) | 48 (37–58.5) | 0.06 | ||
| Male gender | 6 (33.3) | 17 (37.0) | 0.78 | ||
| Median Charlson index (IQR) | 0 (0–0) | 0 (0–0) | 0.42 | ||
| Diabetes mellitus | 2 (11.1) | 3 (6.5) | 0.61 | ||
| Cancer | 0 | 3 (6.5) | 0.55 | ||
| Recurrent urinary tract infections | 1 (5.6) | 0 | 0.28 | ||
| Dependent for basic activities | 2 (11.1) | 0 | 0.07 | ||
| Bed-ridden | 1 (5.6) | 0 | 0.28 | ||
| Recurrent urinary tract infections | 1 (5.6) | 0 | 0.22 | ||
| Urinary catheter | 0 | 0 | |||
| Usual caregiver of index patient | 11 (61.1) | 21 (45.6) | 0.26 | ||
| Contact with farm animals | 1 (5.6) | 1 (2.2) | 0.48 | ||
| Shared bathroom with index patient | 14 (77.8) | 42 (91.3) | 0.14 | ||
| Travel abroad in the previous 3 months | 0 | 1 (2.2) | 1 | ||
| Sexual partner of index patient | 6 (33.3) | 14 (30.4) | 0.82 | ||
| Mean meal outside home > 3 days/week | 3 (16.7) | 6 (13.0) | 0.70 | ||
| Cook regularly at home | 9 (50) | 22 (47.8) | 0.87 | ||
| Eat chicken products ≥1 per week | 11 (61.1) | 28 (60.9) | 0.98 | ||
| Eat turkey products ≥1 per week | 5 (27.8) | 17 (37.0) | 0.48 | ||
| Eat raw vegetables ≥1 per week | 17 (94.4) | 39 (84.8) | 0.29 | ||
| Recent antibiotic use | 3 (16.7) | 1 (2.2) | 0.06 | ||
| Proton pump inhibitor use | 9 (50.0) | 12 (26.1) | 0.06 | 3.08 (0.88–10.8) | 0.07 |
| Features of index patient (cluster level) | Clusters with one or more ST131 colonized household member ( | Clusters without any ST131 colonized household member ( |
| ||
| Median age in years (IQR) | 79 (69.75–83.75) | 67.5 (51.5–81) | 0.16 | 1.05 (1.01–1.10) | 0.05 |
| Male gender | 8 (61.5) | 8 (38) | 0.43 | ||
| Bed-ridden | 0 | 0 | 0.81 | ||
| Dependent for basic activities | 2 (15.3) | 2 (9.5) | 0.65 | ||
| Urinary catheter | 4 (30.7) | 3 (14.28) | 0.36 | ||
| Median Charlson index (IQR) | 0.5 (0–2) | 1.5 (0–2) | 1 | ||
| Pets at home | 7 (53.8) | 11 (52.4) | 0.96 | ||
| Recent antimicrobial use | 9 (69.2) | 13 (61.9) | 0.84 |
Characteristics of ST131 E. coli colonized and non-colonized hospital contacts of index nosocomial patients. Data are expressed as number of exposed patients (percentage) except where specified
| Features of contacts (individual level) | ST 131 colonized hospital contacts ( | Non-ST131 colonized hospital contacts ( |
| Adjusted OR |
|
|---|---|---|---|---|---|
| Median age in years (IQR) | 81.5 (75.5–87.75) | 6.08 (59.75–80.0) | 0.05 | ||
| Male gender | 5 (50.0) | 20 (45.4) | 0.79 | ||
| Median Charlson index (IQR) | 1 (0.25–5) | 1 (0–3.75) | 0.76 | ||
| Diabetes mellitus | 3 (30.0) | 15 (34.0) | 0.80 | ||
| Cancer | 3 (30.0) | 13 (29.5) | 0.98 | ||
| Liver cirrosis | 0 | 1 (2.2) | 1 | ||
| Recurrent urinary tract infections | 1 (10.0) | 1 (2.2) | 0.34 | ||
| Dependent for basic activities | 5 (50.0) | 3 (6.8) | 0.003 | 21.1 (3.61–160.0) | 0.001 |
| Bed-ridden | 1 (10.0) | 0 | 0.18 | ||
| Shared room with index patient | 7 (70.0) | 24 (54.5) | 0.37 | ||
| Surgery during present admission | 4 (40.0) | 15 (34.0) | 0.72 | ||
| Urinary catheter | 6 (60.0) | 12 (27.2) | 0.19 | 8.4 (0.97–76.9) | 0.05 |
| Recent antimicrobial use | 4 (40.0) | 16 (36.3) | 0.83 | ||
| Proton pump inhibitor use | 6 (60.0) | 34 (77.2) | 0.85 | ||
| Median (IQR) days of hospital stay | 5.5 (4.0–11.25) | 6 (3.75–9) | 0.70 | ||
| Features of index patient (cluster level) | Clusters with at least one ST131 colonized hospital contact ( | Clusters without any ST131 colonized hospital contact ( |
| ||
| Median age in years (IQR) | 62.50 (52.75–78) | 67.10 (58.25–80.75) | 0.70 | ||
| Male gender | 5 (62.5) | 6 (27.3) | 0.28 | ||
| Median Charlson index (IQR) | 2.60 (0–6) | 2.40 (0–6) | 0.7 | ||
| Bed-ridden | 0 | 3 (13.6) | 0.53 | ||
| Dependent for basic activities | 2 (25) | 4 (18.1) | 0.73 | ||
| Admission to a surgical ward | 4 (50) | 8 (36.3) | 0.66 | ||
| Admission to a medical ward | 5 (62.5) | 11 (50) | 0.74 | ||
| Admission to an intensive care unit | 1 (12.5) | 0 | 0.21 | ||
| Surgery during present admission | 4 (50) | 5 (22.7) | 0.39 | ||
| Urinary catheter | 7 (87.5) | 10 (45.4) | 0.76 | ||
| Recent antimicrobial use | 7 (87.5) | 10 (45.4) | 0.42 | ||
| Median (IQR) days of hospital stay | 27.2 (7–46) | 35.5 (14.75–24) | 0.59 |
Antimicrobial susceptibility of ST131 Escherichia coli isolates. Data are number of susceptible isolates (percentage)
| Antimicrobial | All isolates ( | Isolates from household members (n = 18) | Isolates from hospital contacts (n = 10) |
|---|---|---|---|
| Ampicillin | 6 (21.4) | 6 (33.3) | 0 |
| Amoxicillin-clavulanic acid | 9 (31.2) | 9 (50) | 0 |
| Piperacillin-tazobactam | 27 (96.4) | 18 (100) | 9 (90) |
| Ceftriaxone | 22 (78.5) | 15 (83.3) | 7 (70) |
| Ceftazidime | 22 (78.5) | 15 (83.3) | 7 (70) |
| Ertapenem | 28 (100) | 18 (100) | 10 (100) |
| Ciprofloxacin | 9 (32.1) | 6 (33.3) | 3 (30) |
| Gentamicin | 24 (85.7) | 17 (94.4) | 7 (70) |
| Tobramycin | 19 (67.8) | 14 (77.8) | 5 (50) |
| Amikacin | 28 (100) | 18 (100) | 10 (100) |
| Fosfomycin | 28 (100) | 18 (100) | 10 (100) |